17 November 2015 – Curetis N.V., a developer of next-level molecular diagnostic solutions has completed its initial public offering on Euronext in Amsterdam and Euronext in Brussels. At its IPO, Curetis raised EUR 40 million, which will be used for the further development of the company.
An international CMS team in Germany, the Netherlands and Belgium, led by Stefan-Ulrich Mueller (Munich), Philipp Melzer (Frankfurt) and Reinout Slot (Amsterdam), advised Curetis on its IPO. The bank syndicate consisted of RBC Capital Markets, Bank Degroof Petercam and ICF Bank AG. CMS has assisted Curetis since 2009 with multiple financing rounds.
Founded in 2007, Curetis N.V.'s sole subsidiary Curetis AG is a molecular diagnostics company which focuses on the development and commercialisation of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other technologies. To date, Curetis has raised funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany.
The following CMS offices were involved: CMS Munich (Stefan-Ulrich Mueller, Dr Tilman Weichert, Jessica Mohaupt, Dr Tobias Kallmaier, Stefan Lueft, Rebekka Quaas, Dr Daniel Hofmann, Dr Martin Triemel, Dr Johannes Rochner, Dr Matthias Windorfer), CMS Frankfurt (Philipp Melzer, Joerg Baumgartner, Patrick Damanik, Julius Hirtz), CMS Amsterdam (Reinout Slot, Clair Wermers, Marlene Veenman, Bob van Zijl, Erik Vorst, Herman Boersen, Gilbert Joskin, Katja van Kranenburg, Tjeerd Hoekstra), CMS Brussels (Benoit Vandervelde), CMS Stuttgart (Roland Wutzke).
